Literature DB >> 34352038

The degree of polymerization and sulfation patterns in heparan sulfate are critical determinants of cytomegalovirus entry into host cells.

Dipanwita Mitra1, Mohammad H Hasan1, John T Bates1,2, Michael A Bierdeman2, Dallas R Ederer1, Rinkuben C Parmar1, Lauren A Fassero1, Quntao Liang3,4, Hong Qiu5, Vaibhav Tiwari6, Fuming Zhang7, Robert J Linhardt7, Joshua S Sharp3, Lianchun Wang8, Ritesh Tandon1,2,3.   

Abstract

Several enveloped virusn class="Chemical">es, including herpesviruses attach to host cells by initially interacting with cell surface heparan sulfate (HS) proteoglycans followed by specific coreceptor engagement which culminates in virus-host membrane fusion and virus entry. Interfering with HS-herpesvirus interactions has long been known to result in significant reduction in virus infectivity indicating that HS play important roles in initiating virus entry. In this study, we provide a series of evidence to prove that specific sulfations as well as the degree of polymerization (dp) of HS govern human cytomegalovirus (CMV) binding and infection. First, purified CMV extracellular virions preferentially bind to sulfated longer chain HS on a glycoarray compared to a variety of unsulfated glycosaminoglycans including unsulfated shorter chain HS. Second, the fraction of glycosaminoglycans (GAG) displaying higher dp and sulfation has a larger impact on CMV titers compared to other fractions. Third, cell lines deficient in specific glucosaminyl sulfotransferases produce significantly reduced CMV titers compared to wild-type cells and virus entry is compromised in these mutant cells. Finally, purified glycoprotein B shows strong binding to heparin, and desulfated heparin analogs compete poorly with heparin for gB binding. Taken together, these results highlight the significance of HS chain length and sulfation patterns in CMV attachment and infectivity.

Entities:  

Year:  2021        PMID: 34352038     DOI: 10.1371/journal.ppat.1009803

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  7 in total

1.  Protection is not always a good thing: The immune system's impact on gene therapy.

Authors:  Martiela Vaz de Freitas; Lariane Frâncio; Laura Haleva; Ursula da Silveira Matte
Journal:  Genet Mol Biol       Date:  2022-07-15       Impact factor: 2.087

2.  Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection.

Authors:  Dipanwita Mitra; Mohammad H Hasan; John T Bates; Gene L Bidwell; Ritesh Tandon
Journal:  Viruses       Date:  2021-11-15       Impact factor: 5.048

Review 3.  Heparan Sulfate and Sialic Acid in Viral Attachment: Two Sides of the Same Coin?

Authors:  Ivan Emmanuel Ramos-Martínez; Edgar Ramos-Martínez; René Álvaro Segura-Velázquez; Manuel Saavedra-Montañez; Jacquelynne Brenda Cervantes-Torres; Marco Cerbón; Dulce Papy-Garcia; Edgar Zenteno; José Ivan Sánchez-Betancourt
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

Review 4.  Harnessing Human Papillomavirus' Natural Tropism to Target Tumors.

Authors:  Rhonda C Kines; John T Schiller
Journal:  Viruses       Date:  2022-07-28       Impact factor: 5.818

5.  Calcium dobesilate reduces SARS-CoV-2 entry into endothelial cells by inhibiting virus binding to heparan sulfate.

Authors:  Yulia Kiyan; Anna Schultalbers; Ekaterina Chernobrivaia; Sergey Tkachuk; Song Rong; Nelli Shushakova; Hermann Haller
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

Review 6.  Polymers Inspired by Heparin and Heparan Sulfate for Viral Targeting.

Authors:  Miriam Hoffmann; Nicole L Snyder; Laura Hartmann
Journal:  Macromolecules       Date:  2022-09-11       Impact factor: 6.057

7.  CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34+ Cell Mobilization.

Authors:  Olga Ostrovsky; Katia Beider; Yan Morgulis; Nira Bloom; Angel Cid-Arregui; Avichai Shimoni; Israel Vlodavsky; Arnon Nagler
Journal:  Cells       Date:  2021-12-10       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.